Jazz Pharmaceuticals Unveils Late-Breaking Phase 4 Data on Xywav®: New Insights into Narcolepsy Treatment at SLEEP 2025

Reuters

06-10

Jazz Pharmaceuticals Unveils Late-Breaking Phase 4 Data on Xywav®: New Insights into Narcolepsy Treatment at SLEEP 2025

Jazz Pharmaceuticals plc has announced late-breaking Phase 4 data regarding Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of narcolepsy. The data were presented at SLEEP 2025 as part of four abstracts selected for their scientific quality and innovation by the Associated Professional Sleep Societies (APSS). The Phase 4 XYLO study demonstrated reductions in blood pressure when patients with narcolepsy switched from twice-nightly high-sodium oxybate to low-sodium Xywav. Additionally, the DUET trial evaluated the safety and changes in daytime sleepiness in adults with narcolepsy taking dosages of 9-12 grams of Xywav per night. The results contribute to the ongoing evaluation of Xywav's therapeutic benefits and safety profile.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: SF06179) on June 09, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2542538823"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542538823\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2542538823?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-10 06:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542538823","market":"nz","top_or_hot":-1,"title":"Jazz Pharmaceuticals Unveils Late-Breaking Phase 4 Data on Xywav®: New Insights into Narcolepsy Treatment at SLEEP 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jazz Pharmaceuticals Unveils Late-Breaking Phase 4 Data on Xywav®: New Insights into Narcolepsy Treatment at SLEEP 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jazz Pharmaceuticals plc has announced late-breaking Phase 4 data regarding Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of narcolepsy. The data were presented at SLEEP 2025 as part of four abstracts selected for their scientific quality and innovation by the Associated Professional Sleep Societies (APSS). The Phase 4 XYLO study demonstrated reductions in blood pressure when patients with narcolepsy switched from twice-nightly high-sodium oxybate to low-sodium Xywav. Additionally, the DUET trial evaluated the safety and changes in daytime sleepiness in adults with narcolepsy taking dosages of 9-12 grams of Xywav per night. The results contribute to the ongoing evaluation of Xywav's therapeutic benefits and safety profile.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: SF06179) on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jazz Pharmaceuticals Unveils Late-Breaking Phase 4 Data on Xywav®: New Insights into Narcolepsy Treatment at SLEEP 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJazz Pharmaceuticals Unveils Late-Breaking Phase 4 Data on Xywav®: New Insights into Narcolepsy Treatment at SLEEP 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-10 06:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jazz Pharmaceuticals Unveils Late-Breaking Phase 4 Data on Xywav®: New Insights into Narcolepsy Treatment at SLEEP 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jazz Pharmaceuticals plc has announced late-breaking Phase 4 data regarding Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of narcolepsy. The data were presented at SLEEP 2025 as part of four abstracts selected for their scientific quality and innovation by the Associated Professional Sleep Societies (APSS). The Phase 4 XYLO study demonstrated reductions in blood pressure when patients with narcolepsy switched from twice-nightly high-sodium oxybate to low-sodium Xywav. Additionally, the DUET trial evaluated the safety and changes in daytime sleepiness in adults with narcolepsy taking dosages of 9-12 grams of Xywav per night. The results contribute to the ongoing evaluation of Xywav's therapeutic benefits and safety profile.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: SF06179) on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JAZZ","symbol_name":"爵士制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDL84Mnbj:1","article_id":"2542538823","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542538823","pubTimestamp":1749506426,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jazz Pharmaceuticals plc has announced late-breaking Phase 4 data regarding Xywav  oral solution for the treatment of narcolepsy. The data were presented at SLEEP 2025 as part of four abstracts selected for their scientific quality and innovation by the Associated Professional Sleep Societies . The Phase 4 XYLO study demonstrated reductions in blood pressure when patients with narcolepsy switched from twice-nightly high-sodium oxybate to low-sodium Xywav. Additionally, the DUET trial evaluated the safety and changes in daytime sleepiness in adults with narcolepsy taking dosages of 9-12 grams of Xywav per night. The results contribute to the ongoing evaluation of Xywav's therapeutic benefits and safety profile.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investm","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"JAZZ":"爵士制药"},"translate_title":"Jazz Pharmaceuticals公布了Xywav®的最新4期数据：2025年睡眠中发作性睡病治疗的新见解","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAZZ":0.9},"content_text":"Jazz Pharmaceuticals Unveils Late-Breaking Phase 4 Data on Xywav®: New Insights into Narcolepsy Treatment at SLEEP 2025\n    \n\n        Jazz Pharmaceuticals plc has announced late-breaking Phase 4 data regarding Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of narcolepsy. The data were presented at SLEEP 2025 as part of four abstracts selected for their scientific quality and innovation by the Associated Professional Sleep Societies (APSS). The Phase 4 XYLO study demonstrated reductions in blood pressure when patients with narcolepsy switched from twice-nightly high-sodium oxybate to low-sodium Xywav. Additionally, the DUET trial evaluated the safety and changes in daytime sleepiness in adults with narcolepsy taking dosages of 9-12 grams of Xywav per night. The results contribute to the ongoing evaluation of Xywav's therapeutic benefits and safety profile.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: SF06179) on June 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}